Open Calls for Input and Feedback


Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.

At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.

Draft Recommendations

Dojolvi (triheptanoin )

Therapeutic Area: Long-chain fatty acid oxidation disorders
Draft recommendations posted for stakeholder feedback: September 9, 2021
End of feedback period: September 23, 2021
Draft Recommendation

Submit Feedback

 

Leqvio (inclisiran)

Therapeutic Area: Primary hypercholesterolemia
Draft recommendations posted for stakeholder feedback: September 9, 2021
End of feedback period: September 23, 2021
Draft Recommendation

Submit Feedback

 

 

Open Calls for Patient and Clinician Input

Therapeutic Area
Therapeutic Area: mycosis fungoides (MF), Sézary syndrome (SS)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed: